Kinaset Therapeutics secured $103 million in a venture round to advance its lead inhaled JAK inhibitor, KN-002, into a pivotal Phase 2b trial for severe, uncontrolled asthma. The clinical-stage biotech is developing precisely targeted respiratory drugs, with KN-002 designed as a nebulized therapy to inhibit Janus kinases locally in the lungs, aiming to reduce systemic side effects associated with oral JAK inhibitors. Its pipeline also includes KN-001, an inhaled pan-JAK/TYK2 inhibitor in preclinical development for broader pulmonary inflammation. The new capital is earmarked specifically for the upcoming Phase 2b SPIRIT trial of KN-002, which will evaluate its effect on asthma control and exacerbations, with additional funds supporting pipeline expansion and general operations. While the investor syndicate was not disclosed, the substantial round reflects specialized backing for Kinaset's approach to a high-value respiratory market. The financing underscores continued investor appetite for next-generation, localized therapies in immunology that seek to improve upon the safety profiles of systemic blockbusters.